Both companies are riding the AI wave, but one stock offers a better mix of growth momentum and valuation today.

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Dycom is the IBD Stock of the Day as Wall Street focuses on the company's push into the burgeoning data center market from ...

The tech company's powerful mix of a strong core search and advertising business, alongside other fast-growing businesses, ...

Gain insights into growth companies as you explore their rapid earnings growth, key characteristics, and how they stand out ...

SmartScale360 reports that demand for remote talent is reshaping global business growth, driven by evolving employee ...

In recent weeks, MongoDB has attracted renewed attention as multiple research firms reiterated positive views on its business ...